Exploring Key Insights of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Growth Prospects, Emerging Trends, and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Duchenne Muscular Dystrophy (DMD) Therapeutics market size evolved in recent years?
The market for therapeutics associated with Duchenne Muscular Dystrophy (DMD) has seen substantial expansion in the past few years. It is projected to increase from a size of $11.95 billion in 2024 to $16.45 billion in 2025, boasting a compound annual growth rate (CAGR) of 37.6%. This past growth is linked to the escalating occurrence of Duchenne Muscular Dystrophy, increased knowledge surrounding its treatments, a surge in healthcare expenditures, and governmental involvement.
What are the predictions for the duchenne muscular dystrophy (dmd) therapeutics market size in the coming years?
Anticipated to witness considerable development in the near future, the market size of duchenne muscular dystrophy (DMD) therapeutics is projected to reach $47.34 billion in 2029, with a compound annual growth rate (CAGR) of 30.3%. Several factors contributing to this growth encompass rising investments in duchenne muscular dystrophy treatments, the application of combination therapies, the arrival of biomarkers, and the increasing prevalence of screening programs for DMD. Noteworthy trends expected during the forecast period include breakthrough treatments for DMD, the evolution of targeted therapies, the launch of innovative medications and therapies, cutting-edge disease-modifying treatments, and dynamic drug developments.
Get your duchenne muscular dystrophy (dmd) therapeutics market report here!
What key factors are fueling the growth of the duchenne muscular dystrophy (dmd) therapeutics market?
An increase in the amount of clinical trials being conducted is expected to drive the growth of the Duchenne muscular dystrophy (DMD) therapeutics market. Clinical trials, which are crucial in assessing the reliability and effectiveness of new medical procedures, treatments, and drugs on human subjects, have seen a notable increase in relation to DMD. This surge in clinical research and innovation suggests ongoing progress and a comprehensive array of therapeutic options, promising enhanced patient outcomes, greater investment, and faster progression towards Effective Therapies for Duchenne Muscular Dystrophy (DMD). For instance, Clinicaltrials.Gov stated in August 2023 that registered clinical trials had risen to 464,218 from 399,496 in 2021 across all 50 US states and 221 countries. Furthermore, about 31% of the total (142,700) studies were registered in the U.S, and 53% (248,310) were conducted in non-U.S. locations. Therefore, the increase in clinical trials is expected to boost the Duchenne muscular dystrophy (DMD) therapeutics market. The Duchenne Muscular Dystrophy (DMD) Therapeutics Market could be propelled by the rising incidence of genetic disorders, expanding the market’s horizons. Genetic disorders, which emerge due to abnormalities or mutations in a person’s DNA or genetics, could bring about a larger-than-average risk group for Duchenne muscular dystrophy if the trend continues upward. Consequently, there would be a greater demand for DMD-related diagnostic and treatment options. As per the World Health Organization (WHO) in February 2022, birth defects cause the death of approximately 240,000 newborns within the first month of life annually. Moreover, around 170,000 children aged between 1 month and 5 years die due to genetic abnormalities like heart defects, neural tube defects and Down syndrome. Therefore, the increasing prevalence of genetic disorders is likely to fuel the expansion of the Duchenne muscular dystrophy (DMD) market.
How is the global duchenne muscular dystrophy (dmd) therapeutics market divided into key segments?
The duchenne muscular dystrophy (DMD) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Who are the key firms paving the way for growth in the duchenne muscular dystrophy (dmd) therapeutics market?
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Which trends are expected to transform the duchenne muscular dystrophy (dmd) therapeutics market?
Prominent entities in the Duchenne muscular dystrophy (DMD) therapeutics market are embracing innovative technologies to improve the effectiveness and availability of DMD treatments, thereby maintaining their market standing. For example, Bit Bio Ltd., a synthetic biology firm based in the UK, introduced disease model products to promote the progression of Duchenne muscular dystrophy (DMD) treatments in July 2023. The products, referred to as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes featuring genetically altered deletions in the gene responsible for the production of dystrophin protein. The models developed by Bit. Bio, which are reprogrammed from induced pluripotent stem cells (iPSCs), offer a reliable and expansible source of human cells for research, tackling issues related to variability and primary cell sourcing. These models assist the creation of DMD treatments by providing valuable insights into disease processes and potential treatment options. This progress could speed up the efforts of researchers striving to find efficient DMD treatments.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12916
What regions are contributing significantly to the growth of the duchenne muscular dystrophy (dmd) therapeutics market?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Interventional Neurology Devices And Equipment Global Market Report 2024
Central Nervous System Biomarkers Global Market Report 2024
Generic Central Nervous System Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
